ctDNA testing, also known as liquid biopsy, is a less-invasive diagnostic alternative to tissue biopsies and is expected to be applied in tumor diagnosis and prognosis. NGS provides an excellent technology that allows the detection of low levels of ctDNA in the blood in a highly sensitive and specific manner. Creative Biolabs is a world-leading service provider that is committed to offering a full range of NGS-based DNA/RNA sequencing services including ctDNA sequencing for tumor research.